GERMAN COMPANIES REACT TO BKA WARNING
Two leading German drug wholesalers, Gehe of Stuttgart and Sanacorp of Bavaria, have reacted sharply to the recent warning by Germany's Federal Cartel Office (BKA) over alleged obstruction of drug re-imports and parallel imports (Marketletter March 30).
Gehe has said it is not involved in the matter raised by the BKA, since it is no longer interested in drug re-imports, given that generics are a better bargain.
The BKA earlier warned three of the German major wholesale groups about refusing to accept re-imports and parallel imports derived from Eurim-Pharm into their product ranges.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze